R Factor for Liver Injury
ورودیهای بالینی بیمار
حداقل ۱ — حداکثر ۲۰۰۰۰ • واحد: U/L
حداقل ۱ — حداکثر ۲۰۰ • واحد: U/L
حداقل ۱ — حداکثر ۱۰۰۰۰ • واحد: U/L
حداقل ۱ — حداکثر ۵۰۰ • واحد: U/L
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Hepatocellular5–1000
- Mixed2–5
- Cholestatic0–2
The R Factor for Liver Injury calculates evaluating end-stage liver disease severity, short-term mortality, and liver transplant waitlist prioritization. Key inputs include alt. Scores guide managing portal hypertension complications, referring for liver transplant evaluation, and supportive care. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Classifies drug-induced liver injury pattern: >=5 hepatocellular, 2-5 mixed, <=2 cholestatic.
Clinical Indication
The R Factor for Liver Injury is indicated for bedside clinical practice to support Classifies drug-induced liver injury pattern: >=5 hepatocellular, 2-5 mixed, <=2 cholestatic.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with decompensated liver cirrhosis, acute liver failure, portal hypertension, ascites, or end-stage liver disease awaiting organ allocation. Clinical application is indicated across Hepatology clinics, liver transplant assessment centers, gastroenterology wards, and liver ICUs.
Limitations & Contraindications
Due to muscle wasting and reduced hepatic creatine synthesis, serum creatinine routinely underestimates renal dysfunction in cirrhosis.
Clinical Pearls & Action Plan
Preventing spontaneous bacterial peritonitis (SBP), managing variceal hemorrhage, and monitoring hepatic encephalopathy are top clinical priorities.
R = (ALT/ULN) / (ALP/ULN)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| alt | float | Yes | ALT(U/L) |
| alt_uln | float | Yes | ALT upper limit of normal(U/L) |
| alp | float | Yes | Alkaline phosphatase(U/L) |
| alp_uln | float | Yes | ALP upper limit of normal(U/L) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 5–1000 | Hepatocellular | Hepatocellular injury pattern |
| 2–5 | Mixed | Mixed injury pattern |
| 0–2 | Cholestatic | Cholestatic injury pattern |
Evidence-Based References (EBM)
- Danan G, Benichou C. Causality assessment of adverse reactions to drugs. J Clin Epidemiol. 1993;46(11):1323-1330.